Drug Patent Expirations in June 2012
Drug Patent Expirations in June 2012
*Drugs may be covered by multiple patents
| Tradename | Applicant | Generic Name | Patent Number | Patent Expiration |
|---|---|---|---|---|
| IONSYS | Incline Therap | fentanyl hydrochloride | 6,317,629 | Jun 2, 2012 |
| SULAR | Shionogi Inc | nisoldipine | 5,422,123 | Jun 6, 2012 |
| REQUIP XL | Smithkline Beecham | ropinirole hydrochloride | 5,422,123 | Jun 6, 2012 |
| ZYFLO CR | Cornerstone Therap | zileuton | 5,422,123 | Jun 6, 2012 |
| DILACOR XR | Watson Labs | diltiazem hydrochloride | 5,422,123 | Jun 6, 2012 |
| VIGAMOX | Alcon Pharms Ltd | moxifloxacin hydrochloride | 4,990,517*PED | Jun 8, 2012 |
| MOXEZA | Alcon Pharms Ltd | moxifloxacin hydrochloride | 4,990,517*PED | Jun 8, 2012 |
| IMITREX | Glaxosmithkline | sumatriptan | 5,705,520*PED | Jun 10, 2012 |
| LESCOL | Novartis | fluvastatin sodium | 5,356,896*PED | Jun 12, 2012 |
| LESCOL XL | Novartis | fluvastatin sodium | 5,356,896*PED | Jun 12, 2012 |
| TRIZIVIR | Viiv Hlthcare | abacavir sulfate; lamivudine; zidovudine | 5,034,394*PED | Jun 18, 2012 |
| EPZICOM | Viiv Hlthcare | abacavir sulfate; lamivudine | 5,034,394*PED | Jun 18, 2012 |
| ZIAGEN | Viiv Hlthcare | abacavir sulfate | 5,034,394*PED | Jun 18, 2012 |
| CHILDREN’S MOTRIN | Mcneil Cons | ibuprofen | 5,374,659*PED | Jun 20, 2012 |
| MOTRIN | Mcneil Consumer | ibuprofen | 5,374,659*PED | Jun 20, 2012 |
| CHILDREN’S MOTRIN | Mcneil | ibuprofen | 5,374,659*PED | Jun 20, 2012 |
| EDARBYCLOR | Takeda Pharms | azilsartan kamedoxomil; chlorthalidone | 5,736,555 | Jun 25, 2012 |
| NEORAL | Novartis | cyclosporine | 6,258,808 | Jun 25, 2012 |
| EDARBI | Takeda Pharms | azilsartan kamedoxomil | 5,736,555 | Jun 25, 2012 |
| NEORAL | Novartis | cyclosporine | 6,262,022 | Jun 25, 2012 |
Subscribers have access to valuable datasets, including:
- Clinical trial information
- International patent families
- International patent priority and PCT information
- Patent maintenance
- Full-text patent downloads
- Sales data (top 200 drugs)
- Paragraph IV challenges
- Tentative approvals
- Dynamic search capabilities with data export
- More…
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com
In renewing the patents, is it the financial value of patenting process of each particular drugs varies or said to be much more higher from each another based on their sales data? like what if they are top selling drugs in the market that probably make more money when compare with others? and how about those drugs with multiple patents?
well, now some kind of generics/or copied products now have the ability to be manufactured and produced by other company based on the procedure and information regarding the drugs. hence, products can go on sell and have a market to capture.